These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31433936)

  • 1. Ibrutinib and Venetoclax for First-Line Treatment of CLL.
    Kater AP; Levin MD; Niemann CU
    N Engl J Med; 2019 Aug; 381(8):788-789. PubMed ID: 31433936
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib and Venetoclax - Doubling Down on CLL.
    Wiestner A
    N Engl J Med; 2019 May; 380(22):2169-2171. PubMed ID: 31141640
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply.
    Jain N; Gandhi V; Wierda W
    N Engl J Med; 2019 Aug; 381(8):789. PubMed ID: 31433937
    [No Abstract]   [Full Text] [Related]  

  • 4. Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.
    Mauro FR; Foà R
    Lancet Oncol; 2018 Jan; 19(1):7-8. PubMed ID: 29246804
    [No Abstract]   [Full Text] [Related]  

  • 5. Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.
    Jain P; Kanagal-Shamanna R; Konoplev S; Zuo Z; Estrov Z
    Am J Hematol; 2018 Dec; 93(12):1568-1569. PubMed ID: 30152528
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
    Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
    Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
    [No Abstract]   [Full Text] [Related]  

  • 10. [Venetoclax combined with rituximab in the treatment of ibrutinib-resistant patient with chronic lymphocytic leukemia: a case report and literature reviews].
    Ye CJ; Xu WB; Yu Q; Wu C; Huang L; Li JM; Yan H
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):700-702. PubMed ID: 31495144
    [No Abstract]   [Full Text] [Related]  

  • 11. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
    Svanberg R; Ostrowski SR; Nasserinejad K; Kersting S; Dobber JA; Mattson M; Tran HTT; Levin MD; Mous R; Kater AP; Niemann CU
    Leuk Lymphoma; 2020 Dec; 61(14):3422-3431. PubMed ID: 32865439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collectively Answering the Venetoclax BTK Inhibitor Sequencing Question in CLL.
    Rogers KA
    Clin Cancer Res; 2020 Jul; 26(14):3501-3502. PubMed ID: 32366672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New first-line options in CLL.
    Romero D
    Nat Rev Clin Oncol; 2019 Sep; 16(9):526-527. PubMed ID: 31213701
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
    Kater AP; Slinger E; Cretenet G; Martens AW; Balasubramanian S; Leverson JD; Eldering E
    Blood Adv; 2021 Dec; 5(23):5410-5414. PubMed ID: 34555843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new triplet for chronic lymphocytic leukaemia: zanubrutinib-venetoclax-obinutuzumab.
    Rossi D; De Almeida JM
    Lancet Haematol; 2021 Dec; 8(12):e864-e865. PubMed ID: 34826404
    [No Abstract]   [Full Text] [Related]  

  • 20. A new triple threat to CLL.
    Lampson BL; Davids MS
    Blood; 2018 Oct; 132(15):1547-1548. PubMed ID: 30309874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.